Search Results
Mar 12, 2026, 04:54 ET Studie zeigt: FreeStyle Libre Technologie verhilft Menschen mit Typ-2-Diabetes und Basalinsulin zu einem besseren Glukosemanagement
and/or GLP-1 Agonist: the FreeDM2 Study. Abstract at ATTD conference, 11-14 March 2026, Barcelona, Spain.2 Leelarathna et al. Impact of FreeStyle Libre 3 on Sensor-Based Outcomes in Type 2 Diabetes Treated with Basal Insulin plus SGLT-2 Inhibitor and/or GLP-1 Agonist:
More news about: Abbott
Mar 12, 2026, 03:00 ET Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
and/or GLP-1 Agonist: the FreeDM2 Study. Abstract at ATTD conference, 11-14 March 2026, Barcelona, Spain. 2 Leelarathna et al. Impact of FreeStyle Libre 3 on Sensor-Based Outcomes in Type 2 Diabetes Treated with Basal Insulin plus SGLT-2 Inhibitor and/or GLP-1 Agonist:
More news about: Abbott
Mar 11, 2026, 14:31 ET Prisma Health Expands Partnership With Minerra™ Health and Announces Strategic Investment to Scale Obesity Care Platform
aligning clinical and economic performance."Future phases of collaboration include expansion into medical weight management pathways, GLP-1 stewardship models, and employer-sponsored programs.Together, Prisma Health and Minerra Health aim to establish a new operating standard
More news about: Minerra Health
Mar 11, 2026, 10:00 ET Maven Is Opening Its Doors to Women Nationwide
spiral.It's one clinic that supports you based on your full story, not just your latest symptom.GLP-1 Care Designed for WomenGLP-1 medications can be powerful tools. Women's metabolic health is inseparable from hormones, reproductive history, and life
More news about: Maven Clinic
Mar 11, 2026, 09:00 ET Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable for Millions
Andel announced the launch of its app and medication platform, giving companies a new way to make GLP-1s an accessible employee benefit. The company is excited to announce that Eli Lilly and Company's newly-approved Zepbound® KwikPen®
More news about: Andel Co-op, Inc.
Mar 11, 2026, 09:00 ET Bel Invests $200 Million to Double Babybel® Production Capacity in Brookings, South Dakota
portion-sized, convenient and nourishing snacks in the U.S., driven by new dietary guidelines and the growing popularity of protein products and GLP-1 diets in the U.S. As an iconic global brand, Babybel® plays a central role in this transformation—a 100% real cheese snack, made with four ingredients,
More news about: Bel Brands USA
Mar 10, 2026, 14:30 ET Navigate Wellbeing Solutions Introduces Winter 2026 Enhancements Anchored in Culture, Care, and Clinical Wellbeing
before diagnosis through personalized support. This solution integrates with mental health, tobacco cessation, lifestyle, weight management, GLP-1, and condition management coaching programs.Impact-Driven WellbeingNavigate's Winter 2026 enhancements reflect a continued
More news about: Navigate Wellbeing Solutions
Mar 10, 2026, 12:53 ET The Meadows Celebrates 50 Years of Trauma-Focused Care and Clinical Leadership
interventions for patients with complex or co-occurring conditions. The organization is also carefully exploring emerging science, including GLP-1 therapies for addiction, as part of its commitment to advancing the field and providing patients with innovative, evidence-based tools to support
More news about: Meadows Behavioral Healthcare
Mar 10, 2026, 10:03 ET Carrum Health and Virta Health Partner to Deliver Seamless, Full-Spectrum Weight Management Solution for Self-Insured Employers
estimated $425.5 billion in 2023, driven by $146.5 billion in excess medical costs and $243 billion in lost workplace productivity.²GLP-1 medications have emerged as a powerful treatment option, but their cost is placing unprecedented strain on employers. These drugs now account for
More news about: Carrum Health
Mar 10, 2026, 08:13 ET Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
that GDNF improved lipid metabolism biomarkers and preserved key cellular pathways in the liver compared with western diet controls and the GLP-1 agonist Semaglutide.GDNF Restores Elevated Cholesterol Levels to Control-Diet Range in Western Diet–Fed Female MiceFemale
More news about: Hoth Therapeutics, Inc.
Mar 10, 2026, 08:00 ET BMO Hosts Third Annual Metabolic Health Summit on the Future of the GLP-1+ Market
summit reflects the rapid advancement of metabolic, cardiovascular, and cardiometabolic science--including the broad and growing impact of GLP-1–based therapies across obesity, diabetes, heart failure, and renal health. The summit will convene industry-leading BioPharma innovators, experts,
More news about: BMO Financial Group
Mar 10, 2026, 08:00 ET BMO Hosts Third Annual Metabolic Health Summit on the Future of the GLP-1+ Market
summit reflects the rapid advancement of metabolic, cardiovascular, and cardiometabolic science—including the broad and growing impact of GLP-1–based therapies across obesity, diabetes, heart failure, and renal health. The summit will convene industry-leading BioPharma innovators, experts,
More news about: BMO Financial Group
Mar 10, 2026, 08:00 ET Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
favorable benefit to risk profile as a non-invasive option for use as an adjunct to GLP-1 receptor agonist chronic weight management therapies and/or as a monotherapy post cessation of GLP-1 receptor agonist weight management therapies with demonstrated benefits to the liver.Pending
More news about: Lipocine Inc.
Mar 10, 2026, 06:00 ET Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
maintenance therapy.- ASC30 demonstrated a safety and tolerability profile consistent with the GLP-1 drug class.- ASC30 SQ depot formulation is the first GLP-1 to achieve drug class consistent weight loss with once-monthly injection without requiring lead-in weekly injections,
More news about: Ascletis Pharma Inc.
Mar 10, 2026, 06:00 ET 歌禮宣佈其小分子GLP-1R激動劑ASC30的超長效皮下儲庫型制劑針對肥胖適應症的美國II期24周研究獲積極頂線結果
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1rasc30ii24-302709241.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Mar 09, 2026, 08:38 ET Lunakai Naturally Stimulates Endogenous GLP-1 Secretion
Lunakai's PRO GLP-1 Booster. "GLP-1 might feel like a new term," said Sarah D., Founder and CEO of Lunakai, "But in reality, GLP-1 is just a natural hormone we make in our gut that helps us manage our
More news about: Lunakai
Mar 09, 2026, 08:00 ET Hydreight Announces Normal Course Issuer Bid
platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy, hair loss, skincare, sexual health and more. Hydreight
More news about: Hydreight Technologies Inc.
Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
kg/m2. ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists. Study enrollment mostly comprised male participants (88.3%). Different doses (2-14 mg), titrations and dose frequencies
More news about: AbbVie
Mar 07, 2026, 09:00 ET PureHealth Research Launches Doctor-Approved Natural GLP-1 Supplements Collection for Metabolic Support
natural GLP-1 supplements, developed with input from medical professionals and formulated with clinically studied botanicals.Formulated by medical experts to support endogenous GLP-1 production through targeted botanical
More news about: PureHealth Research LLC
Mar 06, 2026, 15:44 ET Studies explore: GLP-1 receptor agonist use and its impact on long-term musculoskeletal health and orthopaedic surgical outcomes
GLP-1 use was also associated with significantly lower surgical site infection rates among patients undergoing TKA and THA. While revision rates were lower among GLP-1 users undergoing TKA, they increased among patients undergoing carpal tunnel release. GLP receptor
More news about: American Academy of Orthopaedic Surgeons
Mar 06, 2026, 11:24 ET Invitation & Agenda: Orexo R&D Day on March 24
AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.
More news about: Orexo
Mar 06, 2026, 11:22 ET Invitation & Agenda: Orexo R&D Day on March 24
AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.
More news about: Orexo
Mar 06, 2026, 08:47 ET Lohman Technologies Announces Deeper Strategic Partnership with Salvo Health to Advance Comprehensive Remote GI Care
HealthSalvo Health delivers continuous, interdisciplinary virtual care for GI and metabolic conditions, including IBS, obesity, GLP-1 management, and MASH/MASLD. Its hybrid model combines a mobile app, dedicated care teams, and seamless coordination with local physicians to drive
More news about: Lohman Technologies
Mar 06, 2026, 08:36 ET Clean Eatz Kitchen Report Finds Most Major Meal Delivery Companies Requires a Subscription - Except One
Kitchen offers chef-prepared, dietitian-designed frozen meals shipped nationwide. Meal plans include Weight Loss, High Protein, Gluten-Free, GLP-1, and Build Your Own, starting at $7.50 per meal. No subscriptions. Free shipping over $85. The brand also sells in 500+ retail locations across the
More news about: Clean Eatz Kitchen
Mar 06, 2026, 01:36 ET Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
LossBased on the globally pioneering cAMP-biased GLP-1 receptor agonism mechanism, Ecnoglutide injection selectively activates the cAMP signaling pathway and minimizes β-arrestin recruitment, distinguishing it from conventional non-biased GLP-1RAs. This mechanism delivers potent and sustained weight
More news about: Sciwind Biosciences Co., Ltd.